The aromatase inhibitor anastrozole inhibits estrogen synthesis. Fulvestrant binds and accelerates degradation of estrogen receptors. We hypothesized that these two agents in combination might be ...

The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib, in combination with fulvestrant therapy, prolongs progression-free survival among patients with hormone-receptor–positive ...

Fulvestrant (‘Faslodex’) is the first of a new type of endocrine treatment – an oestrogen receptor (ER) antagonist that downregulates the ER and has no agonist effects. An understanding of ...

Aug. 19, 2002 — In two randomized trials described in the Aug. 15 issue of the Journal of Clinical Oncology, fulvestrant (Faslodex) was as effective as anastrozole for the treatment of women ...

Credit: AstraZeneca. The approval was based on data from the phase 3 CAPItello-291 trial, which included patients with HR+/HER2- locally advanced or metastatic breast cancer with PIK3CA/AKT1/PTEN ...

“Our study has shown that combining a newer medicine called everolimus [Afinitor] with a more established medicine, fulvestrant [Faslodex], has demonstrated benefit in aromatase inhibitor ...

Patients treated with capivasertib plus fulvestrant had a median progression-free survival of 7.2 months, compared to 3.6 months in patients treated with placebo plus fulvestrant. This amounted to ...

2 In the trial, Truqap in combination with fulvestrant reduced the risk of disease progression or death by 50% versus fulvestrant alone in patients with tumours harbouring PIK3CA/AKT1/PTEN ...

Review the side-effects of Fulvestrant as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of ...

Finding showed the inavolisib-based regimen reduced the risk of disease progression or death by 57% compared with palbociclib and fulvestrant alone. The Food and Drug Administration (FDA ...